Regulatory issues related to marker development

By Taube S.E.   Freiberg G.P.  

Urologic Oncology: Seminars and Original Investigations, Vol. 5, Iss. 5, 2000-09 ,pp. : 214-216

Elsevier

Access to resources Recommend Favorite

The Epstein Barr virus DNA levels as a tumor marker in EBV-associated cancers

By Paoli Paolo   Pratesi Chiara   Bortolin Maria  

Journal of Cancer Research and Clinical Oncology, Vol. 133, Iss. 11, 2007-11 ,pp. : 809-815

Springer Publishing Company

Access to resources Recommend Favorite

Methodological Aspects of Erythrocyte Aggregation

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 2, Iss. 3, 2007-11 ,pp. : 240-245

Bentham Science Publishers

Access to resources Recommend Favorite

CD68 tumor-associated macrophage marker is not prognostic of clinical outcome in classical Hodgkin lymphoma

By Kayal Smita   Mathur Sandeep   Karak Asis K.   Kumar Lalit   Sharma Atul   Bakhshi Sameer   Raina Vinod  

Leukemia and Lymphoma, Vol. 55, Iss. 5, 2014-05 ,pp. : 1031-1037

Informa Healthcare

Access to resources Recommend Favorite

REporting recommendations for tumor MARKer prognostic studies (REMARK)

By McShane Lisa   Altman Douglas   Sauerbrei Willi   Taube Sheila   Gion Massimo   Clark Gary  

Breast Cancer Research and Treatment, Vol. 100, Iss. 2, 2006-11 ,pp. : 229-235

Springer Publishing Company

Access to resources Recommend Favorite